Clinical Trials Logo

Positron-Emission Tomography clinical trials

View clinical trials related to Positron-Emission Tomography.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06453915 Not yet recruiting - Clinical trials for Positron Emission Tomography

NeuroFLiPP: Parametric PET of Neuroinflammation in Fatty Liver Disease

Start date: July 2024
Phase: Early Phase 1
Study type: Interventional

Alzheimer's Disease and related dementias (ADRD) affect about 6 million people in the U.S. and are the fifth leading cause of death for adults over 65. Recent research is investigating how chronic liver diseases like Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which affects one-third of the U.S. population, might influence ADRD through the liver-brain axis. MASLD shares risk factors with Alzheimer's, such as diabetes and hypertension, and studies have linked MASLD to increased risks of cognitive decline and ADRD. Mouse-model studies suggest that chronic liver inflammation in MASLD can induce neuroinflammation and accelerate Alzheimer's pathology, highlighting the importance of studying the liver-brain connection to identify new therapeutic targets for ADRD. The goal of this research is to develop a practical PET imaging method using 18F-FDG to simultaneously assess liver and brain inflammation in patients with MASLD-related ADRD. This approach leverages dynamic FDG-PET scanning and advanced tracer kinetic modeling to quantify glucose transport, overcoming limitations of traditional imaging methods that cannot noninvasively assess chronic liver inflammation. The new method aims to enable comprehensive imaging of liver-brain inflammation crosstalk, validated against the 18F-DPA-714 radiotracer. Success in this project could provide a valuable imaging tool for linking liver inflammation with neuroinflammation and cognitive decline, advancing clinical research and potentially uncovering new pathways for ADRD treatment

NCT ID: NCT06419361 Not yet recruiting - Cancer Clinical Trials

[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients

Start date: May 21, 2024
Phase: Early Phase 1
Study type: Interventional

Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist ([68Ga]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.

NCT ID: NCT05411250 Not yet recruiting - Clinical trials for Positron-Emission Tomography

Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma

Start date: June 1, 2022
Phase:
Study type: Observational

To explore the value of 18F-fluorodeoxyglucose (FDG) PET/CT imaging in early diagnosis of treatment-related cardiotoxicity (TACT) of lymphoma using visual method and semi-quantitative method.

NCT ID: NCT04367948 Not yet recruiting - Lymphoma Clinical Trials

Positron Nuclide Labeled NOTA-FAPI PET Study in Lymphoma

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

To evaluate the normal physiological distribution of positron nuclide labeled NOTA-F API in human body and its detection efficiency for lymphoma